The Multiple Sclerosis Association of America (MSAA) recently published the latest MS Research Update both printed and online at mymsaa.org. This update is a comprehensive overview of research findings on FDA-approved disease-modifying therapies, as well as many experimental treatments for relapsing forms of multiple sclerosis (MS). In the publication, the authors also provide directions for potential new research.
The information provided is based on a wide range of sources, including extensive journal literature on MS and its management, a review of ongoing clinical trials and papers presented at major national as well as international conferences. These include the 2014 conferences hosted by the American Academy of Neurology (AAN), the Consortium of Multiple Sclerosis Centers (CMSC), and the American and European Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS and ECTRIMS).
The 2015 MS Research Update includes fresh evidence about approved disease-modifying therapies (DMTs), and also many experimental drug agents that are now being tested as long-term treatments for multiple sclerosis (MS). Specifically, in the new edition the authors provide information about the recent approval of LEMTRADA® by the FDA for relapsing types of MS, and also label changes the administration introduced for TECFIDERA™. Along with new updates targeting relapsing forms of MS, the MSAA provides updates on current research looking for treatments for progressive forms of the disease.
Importantly, the 2015 MS Research Update provides information on recent studies in different fields of research including therapies for myelin repair and protection, stem-cell research, genetic studies, biomarkers, among others, offering several and more complex treatment options for both healthcare professionals and patients.
Because patient awareness and education is vital for an effective management of MS, the 2015 Research Update, along with other MSAA resources, are valuable tools for those looking for information concerning MS treatment options. More information can be found in the MSAA website at mymsaa.org.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?